Exposure to SB 743921 at 1 nmol/l and 5 nmol/l for 24 h significantly increased the G2/M phase in MDA-MB-231 cells compared with the DMSO control. The same treatment significantly increased the G2/M phase in MCF-7 cells compared with the DMSO control. In KMS20 cells, pretreatment with SB 743921 at 1 nM for the indicated times significantly reduced levels of SOD2, TFAM, Mcl-1, and cyclin D1 compared with control cells. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
G2/M phase in MDA-MB-231 cells
Cell-based study · MDA-MB-231 [1]
MDA-MB-231 cells were exposed to SB 743921 at 1 nmol/l and 5 nmol/l for 24 h. The G2/M phase was significantly increased compared with the DMSO control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 nmol/l, and 5 nmol/l
- Exposure duration
- 24 h
- Method
- exposed to SB743921
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: SB 743921
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Cell lines and chemicals (S3); Materials and methods > Cell-cycle analysis (S19); Results > SB743921 induces cell-cycle arrest and apoptosis in breast cancer cells (S54, S55); Fig. 3 legend (S124)
G2/M phase: G2/M phase; comparator: DMSO control — Results > SB743921 induces cell-cycle arrest and apoptosis in breast cancer cells (S54, S55); Fig. 3 legend (S124)
Expression changes in KMS20 cells
Cell-based study · KMS20 cells [2]
KMS20 cells were pretreated with SB 743921 at 1 nM for the indicated times. Levels of SOD2, TFAM, Mcl-1, and cyclin D1 were significantly reduced compared with control cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 nM
- Exposure duration
- the indicated times
- Method
- pretreated
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: SB 743921
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > SB743921 potently induces cell death in multiple myeloma cells (S9); RESULTS > SB743921 induces cell death via inhibition of the NF-κB signaling pathway (S40); Fig. 3. legend (S91)
Relative expression levels of SOD2, TFAM, Mcl-1, and cyclin D1: Relative expression levels of SOD2, TFAM, Mcl-1, and cyclin D1; comparator: control cells — RESULTS > SB743921 potently induces cell death in multiple myeloma cells (S9); RESULTS > SB743921 induces cell death via inhibition of the NF-κB signaling pathway (S40); Fig. 3. legend (S91)
G2/M phase in MCF-7 cells
Cell-based study · MCF-7 [1]
MCF-7 cells were exposed to SB 743921 at 1 nmol/l and 5 nmol/l for 24 h. The G2/M phase was significantly increased compared with the DMSO control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 nmol/l, and 5 nmol/l
- Exposure duration
- 24 h
- Method
- exposed to SB743921
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: SB 743921
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Cell lines and chemicals (S3); Materials and methods > Cell-cycle analysis (S19); Results > SB743921 induces cell-cycle arrest and apoptosis in breast cancer cells (S54, S55); Fig. 3 legend (S124)
G2/M phase: G2/M phase; comparator: DMSO control — Results > SB743921 induces cell-cycle arrest and apoptosis in breast cancer cells (S54, S55); Fig. 3 legend (S124)
